Tirzepatide was associated with a lower 1-year risk of major adverse cardiovascular events compared with GLP-1 receptor agonists (HR 0.75; 95% CI 0.63-0.91).
Cohort (n=16,402)
Yes
Does tirzepatide reduce 1-year major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease compared with GLP-1 receptor agonists?
Tirzepatide was associated with a significantly reduced 1-year risk of major adverse cardiovascular events compared with GLP-1 receptor agonists in patients with type 2 diabetes and ASCVD.
Hazard Ratio: 0.75 (95% CI 0.63–0.91)
BACKGROUND: To evaluate the association between tirzepatide use and 1-year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP-1 (glucagon-like peptide-1) receptor agonists. METHODS: We conducted a retrospective, propensity score-matched cohort study using the TriNetX network. A total of 16 402 patients with type 2 diabetes and atherosclerotic cardiovascular disease initiating tirzepatide or GLP-1 receptor agonists between January 1, 2022, and March 31, 2025 were matched 1:1. The primary outcome was 1-year major adverse cardiovascular events; secondary outcomes included all-cause mortality, acute myocardial infarction, major adverse limb events, and tissue plasminogen activator use. RESULTS: Tirzepatide was associated with a lower risk of major adverse cardiovascular events (hazard ratio HR, 0.75 95% CI, 0.63-0.91) and reduced risks of all-cause mortality (HR, 0.69 95% CI, 0.53-0.90), major adverse limb events (HR, 0.59 95% CI, 0.39-0.88), and acute myocardial infarction (HR, 0.70 95% CI, 0.53-0.93), compared with GLP-1 receptor agonists. Results were robust across subgroups and sensitivity analyses. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was associated with a significantly reduced 1-year risk of major adverse cardiovascular events and other cardiovascular outcomes compared with GLP-1 receptor agonists. These findings support the cardiometabolic potential of tirzepatide, warranting further prospective validation.
Wu et al. (Fri,) conducted a cohort in Type 2 diabetes and atherosclerotic cardiovascular disease (n=16,402). Tirzepatide vs. GLP-1 receptor agonists was evaluated on 1-year major adverse cardiovascular events (HR 0.75, 95% CI 0.63-0.91). Tirzepatide was associated with a lower 1-year risk of major adverse cardiovascular events compared with GLP-1 receptor agonists (HR 0.75; 95% CI 0.63-0.91).